Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13404864 | 1.00 | KDM4E (0.43) | KDM4EALDH1A1MEN1KMT2AGAA | |
| SCHEMBL24966302 | 1.00 | KDM4E (0.43) | KDM4EALDH1A1MEN1KMT2AGAA | |
| SCHEMBL12019208 | 1.00 | KDM4E (0.43) | KDM4EALDH1A1MEN1KMT2AGAA | |
| SCHEMBL12039539 | 1.00 | KDM4E (0.43) | KDM4EALDH1A1MEN1KMT2AGAA | |
| SCHEMBL18472627 | 1.00 | KDM4E (0.43) | KDM4EALDH1A1MEN1KMT2AGAA | |
| SCHEMBL12391966 | 0.98 | KDM4E (0.40) | KDM4EALDH1A1MEN1KMT2AGAA | |
| SCHEMBL24919553 | 0.91 | KDM4E (0.38) | KDM4EALDH1A1MEN1KMT2AGAA | |
| SCHEMBL20614612 | 0.91 | KDM4E (0.38) | KDM4EALDH1A1MEN1KMT2AGAA | |
| SCHEMBL24919562 | 0.91 | KDM4E (0.38) | KDM4EALDH1A1MEN1KMT2AGAA | |
| SCHEMBL26426519 | 0.87 | KDM4E (0.38) | KDM4EALDH1A1MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130109019-A1 | HAPTEN CONJUGATES FOR TARGET DETECTION | VENTANA MEDICAL SYSTEMS, INC. | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109019-A1 | HAPTEN CONJUGATES FOR TARGET DETECTION | TYR, TH, TYRO3 | KDM4E 2694/4885ALDH1A1 1205/4885MEN1 4775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.